Medovate Ltd has signed a distributor agreement with 20/20 Imaging, a division of Konica Minolta Healthcare Americas Inc. to make its technology for regional anaesthesia available across the veterinary market in the USA.
The SAFIRA system was originally developed for human patient use in hospitals, but huge potential for its unique benefits to be extended to veterinary regional anaesthesia has also been identified.
Medovate has worked with 20/20 Imaging to engage with veterinary professionals in the States to gain insights and understanding around the potential for the SAFIRA technology to revolutionise veterinary regional anaesthesia practice.
20/20 Imaging is the first company to be appointed as a distributor for the SAFIRA system in the veterinary market and will now bring the unique patient and clinical benefits that the technology offers in human healthcare to veterinarians in the USA, focusing on small-animal regional anaesthesia.
In current regional anaesthesia procedures two operators are often needed, including a second operator (an assistant) who injects the anaesthetic solution at the required pressure, which relies on ‘feel’.
This means anaesthetic solutions can be injected at high pressures which can increase risk of nerve injury.
SAFIRA enables the veterinary practitioner to control the injection themselves, without the need for an assistant to control the syringe.
It also incorporates a pressure monitoring system which automatically stops injection at a calibrated threshold.
Another benefit is that the system enables a controlled release of local anaesthetic allowing lower amounts of local anaesthetic to be injected.
Bob Salzman, President 20/20 Imaging said: “This is a ground-breaking new technology for safer regional anaesthesia and is unique in making it a one person procedure and reducing reliance on subjective ‘injection pressure feel’.
“20/20 Imaging are proud to be the first appointed distributor to be bringing its unique benefits to the veterinary market and we look forward to making this exciting technology available to veterinary professionals across America alongside our leading range of ultrasound solutions to enable them to deliver the best care for their patients.”
Regional anaesthesia is an important part of small animal care and is used for many reasons in veterinary medicine, including improved quality of recovery.
The use of ultrasound guided regional anaesthesia is becoming more common practice today, with the technique – which can help provide a higher level of visualisation for the practitioner – increasingly seen as a ‘gold standard’.
There are some limitations and challenges that are not always present in the practice of adult human medicine.
Nerve injury for instance, is harder to ascertain in animals. Small animals such as cats also have increased sensitivity to local anaesthetics when compared with other species, necessitating much lower maximum doses be used.
Stuart Thomson, Managing Director at Medovate said:“With a significant number of regional anesthesia blocks completed in veterinary practice per year around the world, SAFIRA can play a significant role in the future of veterinary regional anesthesia practice.
“We are delighted to be partnering with 20/20 Imaging as our new distributor partner for SAFIRA in the veterinary market in the United States of America and we look forward to working with them roll out this exciting technology to US-based veterinary professionals. It is a very exciting time for our company as we launch our SAFIRA product portfolio into the US veterinary field.”
Developed in collaboration with consultant anaesthesiologists in the UK National Health Service (NHS), SAFIRA has been successfully launched in the human healthcare field in the USA, UK and Europe, Australia and New Zealand, Singapore and the Middle East.
Medovate has also partnered with Konica Minolta Healthcare Americas, Inc. in the human healthcare field to promote best practice within regional anaesthesia across the United States and the Middle East.
